Correction to: Combined pembrolizumab and bevacizumab therapy effectively inhibits non-small-cell lung cancer growth and prevents postoperative recurrence and metastasis in humanized mouse model.

MLA

Qiao, Tianyun, et al. “Correction to: Combined Pembrolizumab and Bevacizumab Therapy Effectively Inhibits Non-Small-Cell Lung Cancer Growth and Prevents Postoperative Recurrence and Metastasis in Humanized Mouse Model.” Cancer Immunology, Immunotherapy, vol. 72, no. 5, May 2023, p. 1183. EBSCOhost, https://doi.org/10.1007/s00262-022-03342-x.

APA

Qiao, T., Zhao, J., Xin, X., Xiong, Y., Guo, W., Meng, F., Li, H., Feng, Y., Xu, H., Shi, C., & Han, Y. (2023). Correction to: Combined pembrolizumab and bevacizumab therapy effectively inhibits non-small-cell lung cancer growth and prevents postoperative recurrence and metastasis in humanized mouse model. Cancer Immunology, Immunotherapy, 72(5), 1183. https://doi.org/10.1007/s00262-022-03342-x

Chicago

Qiao, Tianyun, Jinbo Zhao, Xiangbing Xin, Yanlu Xiong, Wenwen Guo, Fancheng Meng, Hui Li, et al. 2023. “Correction to: Combined Pembrolizumab and Bevacizumab Therapy Effectively Inhibits Non-Small-Cell Lung Cancer Growth and Prevents Postoperative Recurrence and Metastasis in Humanized Mouse Model.” Cancer Immunology, Immunotherapy 72 (5): 1183. doi:10.1007/s00262-022-03342-x.